A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Evangelos Terpos, Prof
Department of Clinical Therapeutics, School of Medicine, National Kapodistrian University of Athens (NKUA)
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Department of Clinical Therapeutics, School of Medicine, National Kapodistrian University of Athens (nkua)
Athens, Greece
Athanasios-Meletios Dimopoulos, ProfessorRecruiting - Anticancer Hospital of Thessaloniki "theageneio"
Thessaloniki, Greece
Eirini Katodritou, Dr.Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 13 Apr 2022
- Primary completion
- 15 Mar 2026
- Completion
- 15 Mar 2026
- Last update posted
- 1 Dec 2023
- Registered enrollment
- 36
- Registry id
- NCT05280275
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.